Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and C-Peptide in this randomized controlled trial publication.

Primary analyses were performed 1 year after UCB infusion.

Treated (N = 10) and control (N = 5) subjects had median ages of 7.2 and 6.6 years, respectively.

Who Took Part

According to the abstract, 15 subjects were involved.

PubMed indexes the participants as infants, young children and children, both men and women.

How the Study Was Run

The design is described as randomized and open-label.

The subjects were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Nothing was hidden in this open-label Vitamin D, K2, Magnesium and Zinc study: the subjects and staff both knew the treatment.

What Was Measured

Primary analyses were performed 1 year after UCB infusion.

The subject headings attached to it are Area Under Curve, C-Peptide, CD4 Lymphocyte Count, Case-Control Studies, Cord Blood Stem Cell Transplantation, Diabetes Mellitus, Type 1 and Docosahexaenoic Acids.

What This Means in Plain Language

The paper is a randomized and open-label study of Vitamin D, K2, Magnesium and Zinc and C-Peptide in 15 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2013 (Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the C-Peptide compound page, all human trials.